Dementia

The behavioral and psychological symptoms of dementia contribute significantly to the greater rates morbidity and mortality among those with dementia.

Here are highlights from the week in Psychiatric Times.

Here are highlights from the week in Psychiatric Times.

Frontal lobe syndrome can present with a range of behaviors that do not meet traditional dementia/neurocognitive disorder criteria.

Here are highlights from the week in Psychiatric Times.

What is the efficacy of ECT for the treatment of dementia?

This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.

The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

“If we can show that serotonin loss over time is directly involved in the transition from mild cognitive impairment to Alzheimer disease, recently developed antidepressant medications may be an effective way to improve memory deficits and depressive symptoms and, thus, may be a powerful way forward to slow disease progression.”

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.

AVP-786, a drug to treat agitation associated with Alzheimer disease dementia, failed to meet the primary efficacy endpoint in a phase 3 clinical trial.

From pain and suicidality in patients with depression to digital mental health interventions for adolescents with eating disorders, here are highlights from the week in Psychiatric Times.

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.

How efficacious is brexpiprazole as a treatment for agitation associated with Alzheimer disease?

Clinicians must feel knowledgeable and masterful in incorporating lifestyle and integrative therapies targeting nutrition, stress reduction, normalization of sleep, aerobic and mindful exercise, and meaningful activities that add joy and life to years, and not just years to life.

Here are highlights from some of the year’s top features in Psychiatric Times from throughout 2023.

In this CME, learn more about the pathophysiology of HIV-associated neurocognitive disorder and to review the research and various tools used to aid in the diagnosis.

Here are some updates from the world of psychiatry throughout the month of November.

What is new in research on psychedelics?

From neurological abnormalities in first-episode psychosis to psychiatric boarding in emergency departments, here are highlights from the week in Psychiatric Times.

What is new in research on dementia?

New positive data for brexpiprazole, the first and only treatment approved to treat agitation associated with dementia due to Alzheimer disease.

What is new in research on sleep?

The drug’s developer announced that the FDA has made 2 clarifying revisions.

What is new in research on psychiatric care for Latinx patient populations?

What is new in research on attention-deficit/hyperactivity disorder?

From a look at adolescent substance use to special challenges in treating borderline personality disorder during the perinatal period, here are highlights from the week in Psychiatric Times.